Cambria Investment Management, L.P.
Position in EXEL — Exelixis, Inc.
CIK 1529389
Manhattan Beach, CA
Position in EXEL
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,438,871
+$371,598 QoQ
Shares Held
26,445
+6.3% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#304
of 754 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Cambria Investment Management, L.P. holds $8,927,538 across 12 Biotechnology names. EXEL ranks #2 (16.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,593 | $2,281,480 | |
| 2 | EXEL |
Exelixis, Inc.
This page
|
26,445 | $1,438,871 | |
| 3 | CLYM |
Climb Bio, Inc.
|
76,109 | $992,461 | |
| 4 | PTGX |
Protagonist Therapeutics, Inc
|
7,869 | $964,582 | |
| 5 | PTCT |
Ptc Therapeutics, Inc.
|
11,398 | $929,734 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
830 | $517,538 | |
| 7 | RVMD |
Revolution Medicines, Inc.
|
2,443 | $457,525 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
1,700 | $409,649 |
All Filings in EXEL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,438,871 | 26,445 | Shares | Other | 2026-08-14 | |
| 2026-03-31 | $1,067,273 | 24,884 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $1,179,508 | 26,911 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $967,824 | 23,434 | Shares | Other | 2025-12-01 | |
| 2025-06-30 | $858,192 | 19,469 | Shares | Other | 2025-08-13 | |
| 2025-03-31 | $731,052 | 19,801 | Shares | Other | 2025-05-15 | |
| No filing history on record for this holder in this stock. | ||||||